20 results on '"Ben Abid Hela"'
Search Results
2. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience
- Author
-
Ramzi Jeddi, Lamia Aissaoui, Ramzi Ben Amor, Emna Gouider, Ben Abid Hela, Ali Saad, Samia Menif, Hafsia Raouf, Balkis Meddeb, Hend Ben Neji, Ben Lakhal Raihane, Karima Kacem, Belhadjali Zaher, Walid Bouteraâ, Hela Ghedira, and Yosr Ben Abdennebi
- Subjects
Adult ,Male ,Acute promyelocytic leukemia ,medicine.medical_specialty ,Tunisia ,Adolescent ,Paraneoplastic Syndromes ,medicine.medical_treatment ,Antineoplastic Agents ,Tretinoin ,Single Center ,Severity of Illness Index ,Gastroenterology ,Body Mass Index ,Leukocyte Count ,Young Adult ,Leukemia, Promyelocytic, Acute ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Child ,Survival analysis ,Aged ,Chemotherapy ,business.industry ,Mortality rate ,Myeloid leukemia ,Hematology ,Middle Aged ,medicine.disease ,Survival Analysis ,Leukemia ,Child, Preschool ,Creatinine ,Immunology ,Cytarabine ,Female ,Idarubicin ,business ,medicine.drug - Abstract
Acute promyelocytic leukemia (APL) has now become the most curable of all subtypes of acute myeloid leukemia. A cure rate of 75-80% can be anticipated with a combination of all-trans retinoic acid (ATRA) and anthracyclines. In Tunisia, the ATRA era began in 1998 with the use, consecutively, of two regimens of a combination of ATRA with anthracycline and cytarabine (APL93), and without cytarabine (LPA99). From 2004, 39 patients with confirmed APL either by t(15;17) or PML/RARA were treated by the PETHEMA LPA 99 trial. The rationale of this protocol by avoiding cytarabine is to reduce death in complete remission (CR) without increasing the incidence of relapse. Thirty-three patients achieved CR (84.6%). The remaining six patients were considered as failure due to early death: three caused by differentiation syndrome (DS) and three died from central nervous system hemorrhage. Baseline blood cell count (WBC) >10 x 10(9)/l (P=0.26) and creatinine >1.4 mg/dl (P=0.42) were not predictive of mortality. DS was observed in 11 patients (30.5%) with a median onset time of 12 days (range: 3-23 days) and median WBC of 29 x 10(9)/L (range: 1.2 x 10(9)-82.7 x 10(9)/l). DS was severe in seven cases, moderate in four, and fatal in three cases. Body mass index > or =30 (P=0.044) and baseline WBC > or =20 x 10(9)/l (P=0.025) are independent predictors of DS. The median follow-up of this study is 36 months. Thirty patients are alive in continuous complete remission; two patients died in CR from septic shock and secondary myelodysplastic syndrome respectively; one patient died 47 months after achieving two relapses. Event free survival from diagnosis was 80% and overall survival was 82%. Our results are quite acceptable and can be improved by reducing mortality rate.
- Published
- 2010
- Full Text
- View/download PDF
3. Predictive factors of septic shock and mortality in neutropenic patients
- Author
-
Ben Abid Hela, Meddeb Balkis, Benabdennebi Yosr, Aissaoui Lamia, Jeddi Ramzi, Kacem Karima, Belhadjali Zaher, Benlakhal Raihane, and Zarrouk Mohamed
- Subjects
Adult ,Male ,medicine.medical_specialty ,Neutropenia ,Fever ,Bacteremia ,Gastroenterology ,Sepsis ,Risk Factors ,Internal medicine ,Pneumonia, Bacterial ,medicine ,Humans ,Lactic Acid ,Fever of unknown origin ,Risk factor ,Bacteria ,business.industry ,Septic shock ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Shock, Septic ,Surgery ,Bicarbonates ,Leukemia, Myeloid, Acute ,Amikacin ,Shock (circulatory) ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Neutropenia is a major risk factor for developing a serious infection. Bacteremia still causes significant mortality among neutropenic patients with cancer. The purpose of this study was to identify risk factors for septic shock and for mortality in neutropenic patients with leukemia and bacteremia. Consecutive samples from 20 patients with acute myeloid leukemia and bacteremia were studied during a 1 year period (January-December 2003). All patients received empirical antibiotic therapies for febrile episodes using ceftazidime plus amikacin. About 110 neutropenic febrile episodes were noted: clinically documented 14.54%, microbiologically documented 16.36% and fever of unknown origin 69.09%. Gram-negative organism caused eight febrile episodes: Pseudomonas (5), Klebsiella (3). Gram-positive organism caused 10 episodes: Staphylococcus (6), Streptococci (2), Enterococci (2). Pulmonary infection accounted for 25% of clinically documented infections. About 14 of the 110 febrile episodes were associated with septic shock causing mortality in 7 patients. In a univariate analysis variables associated with septic shock were: pulmonary infection (OR = 17, p = 0.001), serum bicarbonate17 mmol/l (OR = 68, p0.001) and serum lactate3 mmol/l (OR = 62, p0.001). Variables associated with mortality were: pulmonary infection (OR = 83, p0.001) and serum bicarbonate17 mmol/l (OR = 61, p0.001). In a multivariate analysis two variables were associated with septic shock: pulmonary infection (OR = 5, p = 0.043) and serum lactate3 mmol/l (OR = 10, p = 0.003). An elevated serum lactate (3 mmol/l) and low serum bicarbonate (17 mmol/l) at the onset of bacteremia are useful biomarkers in predicting septic shock and mortality in neutropenic patients.
- Published
- 2007
- Full Text
- View/download PDF
4. Fanconi anemia in Tunisia: high prevalence of group A and identification of new FANCA mutations
- Author
-
Bouchlaka, Chiraz, Abdelhak, Sonia, Amouri, Ahlem, Ben Abid, Hela, Hadiji, Sondes, Frikha, Mounir, Ben Othman, Tarek, Amri, Fethi, Ayadi, Hammadi, Hachicha, Mongia, Rebaï, Ahmed, Saad, Ali, Dellagi, Koussay, Group, Tunisian Fanconi Anemia Study, Laboratoire d'Immunopathologie, Vaccinologie et Génétique Moléculaire (LVGM), Institut Pasteur de Tunis, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Hôpital Universitaire Aziza Othmana [Tunis], Hedi Chaker Hospital [Sfax], Hopital Habib Bourguiba - Habib Bourguiba Hospital [Sfax], Centre National de Greffe de la Moëlle osseuse Tunis (CNGMO), Hôpital de Kairouan, Faculté de médecine - Faculty of Medicine [Sfax, Tunisie] (FMS), Université de Sfax - University of Sfax, Centre de Biotechnologie de Sfax (CBS), CHU Farhat Hached [Sousse], This work was supported by founds from the Tunisian State Secretariat for Scientific and Technological Research., We acknowledge the participation to this investigation of other members of the Tunisian Fanconi Anemia Study Group, and namely Dr. L. Aissaoui, Dr. R. Belakhal, Dr. Z. Belhaj Ali, Dr. B. Meddeb, Dr. A. Hafsia, Dr. M. Elloumi, Dr. F. Fakhfakh PhD, Dr. A. Abdelkafi, Dr. L. Tordjman, Dr. F. Mellouli, Dr. S. Ladeb, Dr. A. Ben Abdeladhim, Dr. H. Sennana, Dr. H. Elghezal, Dr. H. Elomri, Dr. A. Laatiri, Dr. A. Khelif, Dr. S. Ennabli, and Dr. M. Trudi. We thank N. Labbane, S. Chakroun, and M. Ben Fadhel, for their technical assistance. We gratefully acknowledge patients and their families for their participation in this study. We thank Hans Joenje for fruitful discussion
- Subjects
Male ,MESH: Sequence Analysis, DNA ,Time Factors ,MESH: Introns ,Genetic Linkage ,DNA Mutational Analysis ,MESH: Base Sequence ,MESH: Genetic Markers ,MESH: Genotype ,FANCE ,FANCF ,Fanconi anemia ,FANCG ,hemic and lymphatic diseases ,MESH: DNA, Complementary/metabolism ,MESH: DNA Mutational Analysis ,Genetics (clinical) ,Genetics ,Fanconi Anemia Complementation Group A Protein ,Homozygote ,Chromosome Mapping ,Exons ,Disease gene identification ,DNA-Binding Proteins ,Phenotype ,MESH: DNA-Binding Proteins ,Female ,MESH: Homozygote ,Genetic Markers ,MESH: Fanconi Anemia/genetics ,Fanconi anemia, complementation group C ,DNA, Complementary ,Genotype ,Molecular Sequence Data ,MESH: Genetic Linkage ,Biology ,MESH: Phenotype ,MESH: Polymorphism, Genetic ,FANCD2 ,medicine ,MESH: Fanconi Anemia Complementation Group A Protein ,Humans ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Alleles ,Family Health ,MESH: Humans ,MESH: Molecular Sequence Data ,Polymorphism, Genetic ,Base Sequence ,MESH: Alleles ,MESH: Time Factors ,Proteins ,MESH: Haplotypes ,Sequence Analysis, DNA ,medicine.disease ,Molecular biology ,MESH: Male ,FANCA ,Introns ,Fanconi Anemia ,MESH: Lod Score ,MESH: Proteins/genetics ,Haplotypes ,MESH: Gene Deletion ,Mutation ,MESH: Mutation ,MESH: Family Health ,MESH: Microsatellite Repeats ,Lod Score ,MESH: Chromosome Mapping ,MESH: Exons ,MESH: Female ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Gene Deletion ,Microsatellite Repeats - Abstract
International audience; Fanconi anemia (FA) is a rare autosomal recessive disease characterized by progressive pancytopenia, congenital malformations, and predisposition to acute myeloid leukemia. Fanconi anemia is genetically heterogeneous, with at least eight distinct complementation groups of FA (A, B, C, D1, D2, E, F, and G) having been defined by somatic cell fusion studies. Six genes (FANCA, FANCC, FANCD2, FANCE, FANCG, and FANCF) have been cloned. Mutations of the seventh Fanconi anemia gene, BRCA2, have been shown to lead to FAD1 and probably FAB groups. In order to characterize the molecular defects underlying FA in Tunisia, 39 families were genotyped with microsatellite markers linked to known FA gene. Haplotype analysis and homozygosity mapping assigned 43 patients belonging to 34 families to the FAA group, whereas one family was probably not linked to the FANCA gene or to any known FA genes. For patients belonging to the FAA group, screening for mutations revealed four novel mutations: two small homozygous deletions 1693delT and 1751-1754del, which occurred in exon 17 and exon 19, respectively, and two transitions, viz., 513G−\textgreaterA in exon 5 and A−\textgreaterG at position 166 (IVS24+166A−\textgreaterG) of intron 24. Two new polymorphisms were also identified in intron 24 (IVS24-5G/A and IVS24-6C/G).
- Published
- 2003
- Full Text
- View/download PDF
5. Scrotal ulcerations during all-transretinoic acid therapy for acute promyelocytic leukemia
- Author
-
Aissaoui Lamia, Belhadj Ali Zaher, Ben Neji Hend, Ben Abid Hela, Meddeb Balkis, Jeddi Ramzi, and Ben Lakhal Raihane
- Subjects
Acute promyelocytic leukemia ,medicine.medical_specialty ,Hematology ,business.industry ,Retinoic acid ,General Medicine ,medicine.disease ,Pericardial effusion ,Gastroenterology ,Procalcitonin ,chemistry.chemical_compound ,chemistry ,Internal medicine ,medicine ,Idarubicin ,business ,medicine.drug - Published
- 2007
- Full Text
- View/download PDF
6. TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
- Author
-
Jeddi, Ramzi, primary, Ghédira, Hèla, additional, Ben Amor, Ramzi, additional, Ben Abdennebi, Yosr, additional, Karima, Kacem, additional, Mohamed, Zarrouk, additional, Ben Neji, Hend, additional, Aissaoui, Lamia, additional, Ben Lakhal, Raihane, additional, Ben Salah, Naouel, additional, Menif, Samia, additional, Belhadjali, Zaher, additional, Ben Abid, Hela, additional, Gouider, Emna, additional, Hafsia, Raouf, additional, Saad, Ali, additional, Fenaux, Pierre, additional, and Meddeb, Balkis, additional
- Published
- 2011
- Full Text
- View/download PDF
7. Predictive factors of all-trans-retinoic acid related complications during induction therapy for acute promyelocytic leukemia
- Author
-
Jeddi, Ramzi, primary, Kacem, Karima, additional, Ben Neji, Hend, additional, Mnif, Samia, additional, Gouider, Emna, additional, Aissaoui, Lamia, additional, Ben Amor, Ramzi, additional, Ben Lakhal, Raihane, additional, Ben Abid, Hela, additional, Belhadjali, Zaher, additional, and Meddeb, Balkis, additional
- Published
- 2008
- Full Text
- View/download PDF
8. Fanconi Anemia: Contribution of Molecular Analyses to the Identification of Bone Marrow Graft Donors and the Study of Chimerism in Grafted Patients
- Author
-
Bouchlaka, Chiraz, Othman, Tarek Ben, Aissaoui, Lamia, Elloumi, Houda, Elloumi, Moez, Amouri, Ahlem, Ben Abid, Hela, Hadiji, Sondes, Slama, Hmida, Makni, Hafedh, Saad, Ali, Abdelhak, Sonia, and Dellagi, Koussay
- Abstract
We report on the effectiveness of molecular studies regarding Fanconi anemia (FA) for a better selection of bone marrow graft donors and for post-transplant follow up. Ten unrelated FA patients and their families were analyzed by microsatellite markers. In 9 cases, the cytogenetic investigation of potential human leukocyte antigen (HLA)-identical related donors was normal, and the molecular analyses confirmed that they were also either normal or heterozygous carriers. For 1 patient, cytogenetic analysis of an HLA-identical sibling donor yielded ambiguous results with a relatively high number of chromosomal breakages using cross-linking agents. However, genotyping of this potential donor demonstrated his heterozygous state. Nine patients have received allogeneic bone marrow transplantation from HLA-matched related donors. Microsatellite analysis showed complete chimerism (CC) in all cases. The median follow up was 54 months (range 8–144 months). One patient out of 9 with CC rejected her graft without prior detection of a transitional mixed chimerism. Among these patients, 1 died 25 months after the transplantation of a chronic graft-versus-host-disease (GVHD). We conclude that, when the cytogenetic studies are not conclusive, molecular analyses are crucial to distinguish heterozygous carriers from asymptomatic FA Tunisian patients. Molecular analyses also allowed the evaluation of hematopoietic chimerism after allogeneic bone marrow transplantation and might be of value to identify patients with a high risk for graft rejection.
- Published
- 2004
- Full Text
- View/download PDF
9. [Malignant external otitis due to Aspergillus niger in leukemic patient: a case report].
- Author
-
Zriba S, Jeddi R, Kacem K, Ben Neji H, Aissaoui L, Ben Lakhal R, Belhadj Ali Z, Ben Abid H, Battikh R, and Meddeb B
- Subjects
- Adult, Female, Humans, Aspergillosis complications, Aspergillus niger, Otitis Externa microbiology, Precursor Cell Lymphoblastic Leukemia-Lymphoma complications
- Published
- 2014
10. [Hemolytic auto immune anemia due do Ig A autoatibodies].
- Author
-
Ben Salah N, El Borgi W, Ben Lakhal F, Ben Abid H, Gouider E, and Hafsia R
- Subjects
- Aged, Female, Humans, Anemia, Hemolytic, Autoimmune diagnosis, Autoantibodies immunology, Immunoglobulin A immunology
- Published
- 2013
11. [Evolution of a refractory cytopenia with multilineage dysplasia and ring sideroblasts to chronic myelomonocytic leukemia].
- Author
-
Ben Salah N, Gouider E, Belakhal F, El Borgi W, Menif S, Ben Abid H, Jeddi R, and Hafsia R
- Subjects
- Humans, Male, Middle Aged, Pancytopenia, Anemia, Refractory pathology, Anemia, Sideroblastic pathology, Myelodysplastic Syndromes pathology
- Published
- 2011
12. [Cytology and immunophenotype feautures of 80 acute myeloid leukemia].
- Author
-
Gouider E, Ayari S, Bouhoula S, Ben Abid H, Ali ZB, Meddeb B, Hafsia A, and Hafsia R
- Subjects
- Adolescent, Adult, Antigens, CD19 analysis, Antigens, CD34 analysis, B-Lymphocytes pathology, CD56 Antigen analysis, Child, Child, Preschool, Female, HLA-DR Antigens analysis, Humans, Immunohistochemistry, Immunophenotyping, Leukemia, Myeloid, Acute classification, Leukemia, Myeloid, Acute immunology, Male, Middle Aged, Myelodysplastic Syndromes immunology, Myelodysplastic Syndromes pathology, Myeloid Cells pathology, Peroxidase analysis, Prognosis, T-Lymphocytes pathology, Leukemia, Myeloid, Acute pathology
- Abstract
Acute myeloid leukemia (AML)'s diagnosis is clinical and biological. We report here 80 AML with cytology and immunophenotype features to establish correlations. 21 AML1, 23 AML2, 12 AML3, 2 AML4, 18 AML5 and 3 AML6 were diagnosed by cytology. Only one case of AML0 was diagnosed by immunophenotype. Myelogysplasia is present in 29.8% cases. CD19 and CD56 expression was significantly associated to AML +t(8;21). Additionally, concomitant negativity of CD34 and HLA-DR was discrimininatif to AML3 diagnosis. Prognostic value to expression some CD needs time backwards.
- Published
- 2007
13. [Hemoglobin C disease: report of 16 Tunisian cases].
- Author
-
Hafsia R, Marrakchi O, Ben Salah N, Gouider E, Ben Lakhal R, Jeddi R, Aissaoui L, Belhadjali Z, Ben Abid H, Meddeb B, and Hafsia A
- Subjects
- Adolescent, Adult, Female, Hemoglobin C analysis, Hemoglobin C Disease genetics, Humans, Hypersplenism etiology, Male, Middle Aged, Retrospective Studies, Splenomegaly etiology, Tunisia, Hemoglobin C Disease diagnosis
- Abstract
Aim: was to provide the clinical and biological patterns hemoglobine disease in Tunisia., Methods: This retrospective study collected to 16 cases of hemoglobin C disease : 6 homozygotic Hb C and 10 heterozygotic Hb C/beta-thalassemia., Results: The clinical profile is characterized by mild hemolytic anemia (Hb = 11.7 g/dl) associated with splenomegaly and hypersplenism. Contrary to homozygous state, the Hb C/beta-thalassemia is associated with microcytosis and pseudopolycythemia. The diagnosis is based on target cells, specific intraerythrocytic Hb C crystals in blood smear and Hb C level at 100%., Conclusion: The Hb C disease must be considered as a benign hemoglobinopathy which is associated with a long survival without major complications.
- Published
- 2007
14. [Tumor lysis syndrome].
- Author
-
Jeddi R, Ben Abdennebi Y, Allani B, Belakhal R, Aissaoui L, Ben Abid H, Ali ZB, and Meddeb B
- Subjects
- Acute Kidney Injury etiology, Acute Kidney Injury therapy, Allopurinol therapeutic use, Antimetabolites therapeutic use, Fluid Therapy, Humans, Tumor Lysis Syndrome complications, Water-Electrolyte Imbalance etiology, Water-Electrolyte Imbalance therapy, Tumor Lysis Syndrome etiology, Tumor Lysis Syndrome therapy
- Abstract
Tumor lysis syndrome is a potentially life threatening oncologic emergency that requires immediate medical intervention. The syndrome results from the destruction (or lysis) of a large number of rapidly dividing malignant cells spontaneously or during chemotherapy. The resulting metabolic abnormalities include hyperkaliemia, hyperuricemia, and hyperphosphatemia with secondary hypocalcemia, all of which put patients at risk for renal failure and alteration in cardiac function. The tumor lysis syndrome occurs most often in patients with large tumor burdens that are very sensitive to chemotherapy and radiotherapy, such as acute or chronic leukaemias with high leukocyte counts and high-grade lymphoma. The current standard management for tumor lysis syndrome consists of allopurinol or recombinant urate oxidase for high risk patient in conjunction with i.v. hydratation with or without alkalinization.
- Published
- 2007
15. [Pseudotumor cerebri with all-trans retinoic acid. A case report].
- Author
-
Jeddi R, Kacem K, Ben Lakhal R, Aissaoui L, Ben Abid H, Belhadj Ali Z, and Meddeb B
- Subjects
- Adult, Female, Humans, Antineoplastic Agents adverse effects, Pseudotumor Cerebri chemically induced, Tretinoin adverse effects
- Abstract
The diagnosis of pseudotumor cerebri (PC) is based on the triad of: (1) papilledema, (2) elevated intracranial pressure with a normal cerebrospinal constituency and (3) normal central nervous system imaging studies. It is an uncommon complication of all-trans-retinoic acid (ATRA) therapy in children treated for acute promyelocytic leukaemia (APL). Its occurrence is rare among adult patients with APL and treated with ATRA . We report a case of an adult with APL who developed PC during induction therapy with ATRA-PC was managed with repeated lumbar punctures and corticotherapy.
- Published
- 2006
16. [Therapeutic results with apl 93 protocol in acute promyelocytic leukemia (34 cases)].
- Author
-
Jeddi R, Hdiji S, Kacem K, Ben Lakhal R, Aissaoui L, Ben Abid H, Belhadj Ali Z, and Meddeb B
- Subjects
- Adolescent, Adult, Anthracyclines administration & dosage, Child, Chromosomes, Human, Pair 15 genetics, Chromosomes, Human, Pair 17 genetics, Female, Humans, Leukemia, Promyelocytic, Acute diagnosis, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute mortality, Male, Middle Aged, Pilot Projects, Receptors, Retinoic Acid, Remission Induction, Retinoic Acid Receptor alpha, Retrospective Studies, Survival Analysis, Translocation, Genetic, Tretinoin administration & dosage, Tunisia, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Promyelocytic, Acute drug therapy
- Abstract
Background: Acute promyelocytic leukaemia (APL) account for approximately 10% to 15% of all AML in most reports. Clinical features includes the presence in 80% to 90% of patients of a severe hemorrhagic syndrome, a specific balanced translocation between chromosomes 15 and 17 with a fusion of a large pert of the retinoic acid receptor a gene (RARa) on chromosome 17 to a part of the promyelocytic leukaemia (PML) gene on chromosome 15. More than 75% of patients (under 65 years of age) can be cured, with the application of a combination of anthracyclines and all-trans retinoic acid (ATRA), followed by maintenance therapy., Aim: of the study was to assess of the therapeutic management of APL 93 protocol in acute promyelocytic leukemia., Methods: We present here the results of a retrospective study concerning 34 patients with APL included between 1998 and 2004 in the APL 93 protocol : 20 in group B and 14 in group C. CR was 82 %., Results: Failure is only due to toxic death (18%) Event free survival at 4 years is 63,47% with relapse rate at 14.25%. Overall survival at 4 years is 69,72%. Our results are acceptable and can be improved with reduction of failure due to toxic death, probably with omission of cytarabine from induction and consolidation adapted by the Spanish PETHEMA Group.
- Published
- 2006
17. Megaloblastic anemia in North Africa.
- Author
-
Maktouf C, Bchir A, Louzir H, Mdhaffer M, Elloumi M, Ben Abid H, Meddeb B, Makni F, Laatiri A, Soussi T, Hafsia A, and Dellagi K
- Subjects
- Adolescent, Adult, Africa, Northern epidemiology, Age Factors, Aged, Aged, 80 and over, Anemia, Megaloblastic classification, Anemia, Pernicious, Child, Child, Preschool, Female, Humans, Infant, Male, Middle Aged, Prospective Studies, Vitamin B 12 Deficiency, Anemia, Megaloblastic epidemiology
- Abstract
We prospectively studied 478 patients with megaloblastic anemia living in Tunisia. Overall, 98% of patients had vitamin B12 deficiency. Pernicious anemia accounted for most of these cases, and median age at presentation was 45 years. Megaloblastic anemia occurred in 19 subjects under 15 years of age, and of these, nine had the Immerslund-Graesbeck syndrome.
- Published
- 2006
18. [Alpha interferon in children with Philadelphia chromosome-positive chronic myeloid-leukaemia].
- Author
-
Ben Lakhal R, Aissaoui L, Jeddi R, Ayari B, Ben Abid H, Belhadj Ali Z, Gouider E, Meddeb B, Hafsia R, and Hafsia A
- Subjects
- Antineoplastic Agents adverse effects, Child, Child, Preschool, Female, Humans, Interferon-alpha adverse effects, Male, Survival Analysis, Treatment Outcome, Antineoplastic Agents therapeutic use, Interferon-alpha therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Abstract
The present work focuses on the therapeutic efficacy and the toxicity of alpha interferon in patients younger than age 18 years. 5 patients younger than 18 years were treated and followed up between 1990 and 1999 at the department of haematology (Aziza Othmana Hospital) Hydroxyurea was given as initial treatment to all patients. After a median period of 8 months, these patients received alpha interferon (5 millions units/m2 once). Six months after the beginning of the alpha interferon a complete hematologic response was obtained in all patients. The median overall survival was of 66 months: 3 patients are still alive (2 patients in an advanced stage and one patient in chronic phase) and 2 patients died after transformation. The most common reported side effects of alpha interferon were asthenia, weight loss, fever, myalgia, chills and headaches--these toxic manifestations were mild and were noticed in all our patients. Myelosuppression was noted in two patients. Interferon is well tolerated in patients younger than age years 18 old, with CML. It may offer an alternative to bone marrow transplantation in children in the chronic phase of CML without histocompatible donor. The role of new agents such as STI 571 needs to be evaluated as well.
- Published
- 2005
19. Granulocytic sarcoma of the small intestine in a child without leukemia: report of a case with cytologic findings and immunophenotyping pitfalls.
- Author
-
Mrad K, Abid L, Driss M, Ben Abid H, and Ben Romdhane K
- Subjects
- Adolescent, Biomarkers, Tumor metabolism, Biopsy, Fine-Needle, Cell Lineage physiology, Cytoplasmic Granules pathology, Diagnosis, Differential, Diagnostic Errors prevention & control, Female, Humans, Immunohistochemistry, Lymphoma pathology, Mesentery pathology, Myeloid Progenitor Cells pathology, Phenotype, Intestinal Neoplasms pathology, Intestine, Small pathology, Leukemia, Myeloid pathology, Sarcoma, Myeloid pathology
- Abstract
Background: Granulocytic sarcoma is a rare tumor that is often misdiagnosed as it can be confused with lymphoma. It has unique cytologic features independent of the site of the tumor and can be identified on fine needle aspiration., Case: A 13-year old girl without a relevant medical history presented with an abdominal mass. Investigation revealed a tumor infiltrate in the small intestine and mesentery. The fine needle aspirate contained myeloid blasts with cytoplasmic granules. Immunohistochemistry on subsequent biopsy confirmed myeloid differentiation. There was no evidence of blood or bone marrow involvement suggestive of acute leukemia. The patient was well after 27 months of follow-up., Conclusion: Granulocytic sarcoma should be included in the differential diagnosis of any small intestine infiltrate. Cytomorphology is accurate and efficient for the diagnosis in conjunction with complete immunocytochemistry study.
- Published
- 2004
- Full Text
- View/download PDF
20. [Bronchopulmonary aspergillosis: study of 17 cases].
- Author
-
Ben Abdallah R, Belhadj S, Kallel K, Boussen N, Ghobantini A, Merai S, Baccar MA, Zouiten F, Ben Abid H, Bejaoui M, Ben Dridi MF, Barsaoui S, Daghfous J, Ben Chaabane T, and Chaker E
- Subjects
- Adult, Aged, Aspergillosis, Allergic Bronchopulmonary etiology, Aspergillus fumigatus isolation & purification, Aspergillus fumigatus pathogenicity, Asthma complications, Female, Humans, Hypersensitivity complications, Male, Middle Aged, Neoplasms complications, Retrospective Studies, Risk Factors, Aspergillosis, Allergic Bronchopulmonary pathology
- Abstract
Aspergillosis is a fungic infection depending on the local or general physiologic and immunologic state of the host. We report the result of retrospective five year study (1995-1999) about 17 cases in the laboratory of Parasitology-Mycology of Rabta hospital in Tunis. Six aspergillomas were observed, they occurred after a pulmonary tuberculosis, two cases of allergic broncho-pulmonary aspergillosis described in two asthmatic patients, nine cases of invasive pulmonary aspergillosis complicating two cancers, one leukaemia, six chronic granulomatous disease. Aspergillus fumigatus is the most frequent species (67%). The clinical and biological characteristic of those will be studied, and compared with those of the literature.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.